Maintenance Dialysis Population Dynamics: Current Trends and Long-Term Implications

ABSTRACT. Despite a general recognition that treatment of end-stage renal disease (ESRD) has become a large-scale undertaking, the size of the treated population and the associated costs are not well quantified. This report combines data available from a variety of sources and places the current (midyear 2001) estimated global maintenance dialysis population at just over 1.1 million patients. The size of this population has been expanding at a rate of 7% per year. Total therapy cost per patient per year in the United States is approximately $66,000. Assuming that this figure is a reasonable global average, the annual worldwide cost of maintenance ESRD therapy in the year 2001, excluding renal transplantation, will be between $70 and $75 billion US dollars. If current trends in ESRD prevalence continue, as seems probable, the ESRD population will exceed 2 million patients by the year 2010. The care of this group represents a major societal commitment: the aggregate cost of treating ESRD during the coming decade will exceed $1 trillion, a thought-provoking sum by any economic metric.

[1]  F. Bach,et al.  Factors in Xenograft Rejection , 1999, Annals of the New York Academy of Sciences.

[2]  M J Lysaght,et al.  Demographic Scope and Economic Magnitude of Contemporary Organ Replacement Therapies , 2000, ASAIO journal.

[3]  A. Rodríguez–Carmona,et al.  The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit. , 1996, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[4]  J. Miller,et al.  Impact of capitation on free-standing dialysis facilities: can you survive? , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  R. Goeree,et al.  Cost analysis of dialysis treatments for end-stage renal disease (ESRD). , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[6]  M. Saul,et al.  The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. , 1998, Journal of the American Society of Nephrology : JASN.

[7]  S. Vukicevic,et al.  Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. , 1998, The Journal of clinical investigation.

[8]  Ulrike Szeimies,et al.  Ancient Egyptian prosthesis of the big toe , 2000, The Lancet.

[9]  W. Heneine,et al.  Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. , 1999, Science.

[10]  W. Mitch Dietary therapy in uremia: the impact on nutrition and progressive renal failure. , 2000, Kidney international. Supplement.